Penumbra Surges to 189th in Trading Volume with $460 Million Turnover

On April 24, 2025, Penumbra (PEN) saw a significant surge in trading volume, with a turnover of $460 million, marking a 97.26% increase from the previous day. This placed Penumbra at the 189th position in terms of trading volume for the day. The stock price of Penumbra rose by 6.99%, marking the third consecutive day of gains, with a total increase of 10.20% over the past three days.

Penumbra Inc. reported a robust revenue growth of 16.3% year-over-year, reaching $324.1 million in the first quarter of 2025. This growth was driven by a 25% increase in U.S. thrombectomy revenue, highlighting the company's strong performance in the domestic market.

The company's adjusted earnings per share (EPS) for the first quarter of 2025 were 83 cents, surpassing estimates by 25.8%. This strong financial performance was further supported by an operating income of $40.4 million and a net income of $39.2 million. The gross margin improved to 66.6%, driven by a favorable product mix and productivity gains.

Penumbra's strategic focus on its thrombectomy products and operational efficiencies contributed to an adjusted EBITDA of $59.6 million, reflecting an 18.4% margin. The company also managed to reduce R&D expenses while increasing SG&A costs, maintaining a robust financial position with $376 million in cash and cash equivalents.

Looking ahead, Penumbra Inc. maintains a positive outlook for 2025, with expectations of continued revenue growth in the U.S. thrombectomy franchise and further improvements in operating and gross margins. This reflects the company's confidence in its strategic initiatives and market position.